trial

D-serine in Schizophrenia

NCTId NCT03702933
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Unknown
Enrollment 40 (estimated)
Sponsored by Herzog Hospital
Primary completion 2021-09-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
40 (estimated)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2018-09-01
Primary completion
2021-09-01
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
D-serine

Sponsors

Herzog HospitalLead Sponsor

Investigators

1
Uriel Heresco-Levy, MDPrincipal Investigator

Sites

1 total
Jerusalem, Israel

Facts & assertions

4 sourced
Enrollment
40
Phase
NA
Primary Completion Date
2021-09-01
Status
UNKNOWN
relationships
The graph out of here
drug
D-serine
drug
lead_sponsor
Herzog Hospital
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Uriel Heresco-Levy, MD
person